Appointment of Non-Executive Director

27 January 2014

Akers Biosciences, Inc.

("ABI" or the "Company")

Appointment of Non-Executive Director

Akers Biosciences, Inc (AIM: AKR, NASDAQ:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Brandon Knox will be appointed to the board as a Non-Executive Director effective immediately.

Brandon Thomas Knox, aged 34, has been a wealth adviser at Raymond James in Philadelphia since December 2012. His practice focuses on investment and estate solutions for high net worth families and individuals as well as public and private institutions both locally and nationally. Prior to joining Raymond James, Mr. Knox was a wealth adviser at Morgan Stanley from July 2008 to October 2012. Between 2006 and 2008, Mr. Knox served as Deputy Finance Director for the Philadelphia mayoral campaign of his father, Thomas Knox. In this role he concentrated on the organisation and management of campaign fundraising efforts as well as the planning and execution of campaign events and off-site functions.

Mr. Knox sits on the Board of Directors of The Committee of Seventy and is a member of the Drexel University Presidents Leadership Council and the Archdiocese of Philadelphia's OSD Advisory Council. Mr. Knox holds a B.S. in Economics from West Chester University and an M.B.A. in Financial Management from Drexel University's LeBow College of Business. 

Mr Knox has not held any other previous directorships in the five years preceding his appointment at ABI.

Commenting on the appointment, Thomas A. Nicolette, Chief Executive Officer said:

"I am delighted to welcome Brandon to the Board of ABI. We believe that Brandon's vast experience with corporate finance and financial management will make him an ideal board member helping the Company to manage its finances as it continues its growth."

Mr Knox is currently beneficially interested in 48,076 common shares of no par value representing 0.98% of the issued share capital of the Company.

There is no further information required relating to Brandon Thomas Knox to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

- ends -

Enquiries:

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com